MedTrace Logo

Infliximab (Remicade) for Patients With Acute Kawasaki Disease

NCT00271570 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-06-14

Study results available
· View outcomes & findings →

Summary

This study evaluates the safety of infliximab in infants and children with acute Kawasaki Disease.

Conditions

  • Kawasaki Disease

Interventions

DRUG

Infliximab (Remicade)

Remicade was 5 mg/kg IV (single dose)

BIOLOGICAL

Intravenous immunoglobulin (IVIG)

2nd dose of IVIG (2g/kg)

Sponsors & Collaborators

Principal Investigators

  • Jane C Burns, M.D. · UCSD/CHHC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2006-10-31
Completion
2006-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00271570 on ClinicalTrials.gov